Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Immunology
Volume 2015, Article ID 816424, 5 pages
http://dx.doi.org/10.1155/2015/816424
Case Report

Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy

Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Lagro Brambilla 3, 50134 Florence, Italy

Received 26 September 2014; Revised 9 January 2015; Accepted 20 January 2015

Academic Editor: Lenin Pavón

Copyright © 2015 Teresa Urraro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Zignego, L. Gragnani, C. Giannini, and G. Laffi, “The hepatitis C virus infection as a systemic disease,” Internal and Emergency Medicine, vol. 7, supplement 3, pp. S201–S208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. L. Zignego, C. Giannini, and L. Gragnani, “HCV and lymphoproliferation,” Clinical and Developmental Immunology, vol. 2012, Article ID 980942, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Bonomo, M. Casato, A. Afeltra, and D. Caccavo, “Treatment of idiopathic mixed cryoglobulinemia with alpha interferon,” The American Journal of Medicine, vol. 83, no. 4, pp. 726–730, 1987. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Ferri, E. Marzo, G. Longombardo et al., “Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial,” Blood, vol. 81, no. 5, pp. 1132–1136, 1993. View at Google Scholar · View at Scopus
  5. R. Misiani, P. Bellavita, D. Fenili et al., “Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus,” The New England Journal of Medicine, vol. 330, no. 11, pp. 751–756, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. V. M. Lauta and A. de Sangro, “Long-term results regarding the use of recombinant interferon alpha-2b in the treatment of II type mixed essential cryoglobulinemia,” Medical Oncology, vol. 12, no. 4, pp. 223–230, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Cacoub, L. Gragnani, C. Comarmond, and A. L. Zignego, “Extrahepatic manifestations of chronic hepatitis C virus infection,” Digestive and Liver Disease, vol. 46, pp. S165–S173, 2014. View at Publisher · View at Google Scholar
  8. A. L. Zignego, L. Gragnani, A. Piluso et al., “Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection,” Expert Review of Clinical Immunology, vol. 11, no. 1, pp. 15–31, 2015. View at Publisher · View at Google Scholar
  9. F. Zaja, S. de Vita, C. Mazzaro et al., “Efficacy and safety of rituximab in type II mixed cryoglobulinemia,” Blood, vol. 101, no. 10, pp. 3827–3834, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Pietrogrande, S. de Vita, A. L. Zignego et al., “Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients,” Autoimmunity Reviews, vol. 10, no. 8, pp. 444–454, 2011. View at Google Scholar · View at Scopus
  11. S. De Vita, L. Quartuccio, M. Isola et al., “A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis,” Arthritis and Rheumatism, vol. 64, no. 3, pp. 843–853, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of hepatitis C virus infection,” Journal of Hepatology, vol. 55, no. 2, pp. 245–264, 2011. View at Publisher · View at Google Scholar
  13. F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for untreated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telaprevir for previously untreated chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2405–2416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Gragnani, A. Fabbrizzi, E. Triboli et al., “Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study,” Digestive and Liver Disease, vol. 46, no. 9, pp. 833–837, 2014. View at Publisher · View at Google Scholar
  16. D. Saadoun, M. R. Rigon, V. Thibault et al., “Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24,” Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 831–837, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. De Nicola, A. Aghemo, M. R. Campise et al., “Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis,” Antiviral Therapy, vol. 19, no. 5, pp. 527–531, 2014. View at Publisher · View at Google Scholar
  18. D. Saadoun, M. Resche Rigon, S. Pol et al., “PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis,” Journal of Hepatology, vol. 62, no. 1, pp. 24–30, 2015. View at Publisher · View at Google Scholar
  19. S. De Vita, F. Soldano, M. Isola et al., “Preliminary classification criteria for the cryoglobulinaemic vasculitis,” Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1183–1190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Piluso, C. Giannini, E. Fognani et al., “Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study,” Journal of Viral Hepatitis, vol. 20, no. 4, pp. e107–e114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Petrarca, L. Rigacci, P. Caini et al., “Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease,” Blood, vol. 116, no. 3, pp. 335–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Saadoun, M. Resche-Rigon, D. Sene, L. Perard, A. Karras, and P. Cacoub, “Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis,” Annals of the Rheumatic Diseases, vol. 67, no. 10, pp. 1431–1436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Terrier, D. Saadoun, D. Sène et al., “Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients,” Arthritis & Rheumatism, vol. 60, no. 8, pp. 2531–2540, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Dammacco, F. A. Tucci, G. Lauletta et al., “Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study,” Blood, vol. 116, no. 3, pp. 343–353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Saadoun, M. R. Rigon, D. Sene et al., “Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia,” Blood, vol. 116, no. 3, pp. 326–334, 504–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Ignatova, O. Chernova, P. Novikov, and S. Moiseev, “HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?” Annals of the Rheumatic Diseases, vol. 73, no. 9, article e58, 2014. View at Publisher · View at Google Scholar
  27. D. Saadoun and P. Cacoub, “HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al,” Annals of the Rheumatic Diseases, vol. 73, no. 9, article e59, 2014. View at Publisher · View at Google Scholar
  28. L. Gragnani, E. Fognani, A. Piluso et al., “Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study,” Hepatology, 2015. View at Publisher · View at Google Scholar
  29. F. Zaja, D. Russo, G. Fuga, F. Patriarca, A. Ermacora, and M. Baccarani, “Rituximab for the treatment of type II mixed cryoglobulinemia,” Haematologica, vol. 84, no. 12, pp. 1157–1158, 1999. View at Google Scholar · View at Scopus
  30. D. Sansonno, V. de Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco, “Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20,” Blood, vol. 101, no. 10, pp. 3818–3826, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Ferri, P. Cacoub, C. Mazzaro et al., “Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature,” Autoimmunity Reviews, vol. 11, no. 1, pp. 48–55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Mauro, M. Pedata, A. Ermacora, and C. Mazzaro, “An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon,” Blood Transfusion, vol. 10, no. 1, pp. 101–103, 2012. View at Publisher · View at Google Scholar · View at Scopus